## Charles D Pusey

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3077226/charles-d-pusey-publications-by-year.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 137
 9,864
 44
 98

 papers
 citations
 h-index
 g-index

 173
 11,568
 7.2
 5.72

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
137	Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization <i>Scientific Reports</i> , <b>2022</b> , 12, 3330	4.9	1
136	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis <i>BMJ, The</i> , <b>2022</b> , 376, e064604	5.9	3
135	The authors reply <i>Kidney International</i> , <b>2022</b> , 101, 648-649	9.9	O
134	Glucocorticoid-free treatment of severe ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2021</b> , 36, 739-742	4.3	2
133	Characterisation of an enhanced preclinical model of experimental MPO-ANCA autoimmune vasculitis. <i>Journal of Pathology</i> , <b>2021</b> , 255, 107-119	9.4	1
132	A Comparison of Pulsatile Hypothermic and Normothermic Ex Vivo Machine Perfusion in a Porcine Kidney Model. <i>Transplantation</i> , <b>2021</b> , 105, 1760-1770	1.8	4
131	Membranous nephropathy associated with viral infection. <i>CKJ: Clinical Kidney Journal</i> , <b>2021</b> , 14, 876-883	34.5	8
130	Validation of the ANCA renal risk score in a London cohort: potential impact of treatment on prediction outcome. <i>Kidney International</i> , <b>2021</b> , 99, 488-489	9.9	3
129	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , <b>2021</b> , 60, 4654-4661	3.9	7
128	Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. <i>Kidney International</i> , <b>2021</b> , 100, 1316-	1324	9
127	A Case Series of Patients with Isolated IgG4-related Hypophysitis Treated with Rituximab. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvaa048	0.4	5
126	Nasal reconstructive surgery for vasculitis affecting the nose: our two-centre international experience. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2020</b> , 277, 3059-3066	3.5	1
125	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary. <i>Rheumatology</i> , <b>2020</b> , 59, 727-731	3.9	3
124	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , <b>2020</b> , 59, e24-e32	3.9	25
123	Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in here-clinical model. <i>Kidney International</i> , <b>2020</b> , 97, 1196-1207	9.9	20
122	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102618	13.6	36
121	Is There a Role for Plasma Exchange in ANCA-Associated Vasculitis?. <i>Current Treatment Options in Rheumatology</i> , <b>2020</b> , 6, 313-324	1.3	3

### (2017-2019)

120	Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. <i>BMC Nephrology</i> , <b>2019</b> , 20, 352	2.7	3
119	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). <i>Kidney International Reports</i> , <b>2019</b> , 4, 1342-1348	4.1	5
118	Membranous Glomerulonephritis With©rescents. <i>Kidney International Reports</i> , <b>2019</b> , 4, 1577-1584	4.1	6
117	Dr. Kang, reply. Journal of Rheumatology, <b>2019</b> , 46, 1244	4.1	
116	Dr. Kang, reply. Journal of Rheumatology, <b>2019</b> , 46, 866-867	4.1	
115	Modification of an aggressive model of Alport Syndrome reveals early differences in disease pathogenesis due to genetic background. <i>Scientific Reports</i> , <b>2019</b> , 9, 20398	4.9	4
114	Plasma exchange in anti-glomerular basement membrane disease. <i>Presse Medicale</i> , <b>2019</b> , 48, 328-337	2.2	6
113	High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 285-293	4.1	30
112	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2019</b> , 34, 63-73	4.3	47
111	Defining Phenotypes in Diabetic Nephropathy: a novel approach using a cross-sectional analysis of a single centre cohort. <i>Scientific Reports</i> , <b>2018</b> , 8, 53	4.9	7
110	Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. <i>Kidney International</i> , <b>2018</b> , 94, 139-149	9.9	47
109	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. <i>Kidney International</i> , <b>2018</b> , 94, 926-936	9.9	2
108	Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 63-72	6.9	33
107	TESTING Corticosteroids in IgA Nephropathy: A Continuing Challenge. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2018</b> , 13, 158-160	6.9	10
106	Antiglomerular Basement Membrane Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2018</b> , 39, 494-503	3.9	11
105	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. <i>Journal of Clinical Apheresis</i> , <b>2018</b> , 33, 638-644	3.2	4
104	Recent advances in understanding of the pathogenesis of ANCA-associated vasculitis. <i>F1000Research</i> , <b>2018</b> , 7,	3.6	8
103	IgA1 Glycosylation Is Heritable in Healthy Twins. <i>Journal of the American Society of Nephrology:</i> JASN, <b>2017</b> , 28, 64-68	12.7	22

102	Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, i123-i128	4.3	21
101	Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, Ifrequency of relapse, and outcomes compared to single-seropositive patients. <i>Kidney International</i> , <b>2017</b> , 92, 693-702	9.9	92
100	Anti-Glomerular Basement Membrane Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2017</b> , 12, 1162-1172	6.9	160
99	Is there a role for TNFB-lockade in ANCA-associated vasculitis and glomerulonephritis?. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, i80-i88	4.3	12
98	Glomerular disease: Crescentic glomerulonephritis: beyond the immune system. <i>Nature Reviews Nephrology</i> , <b>2017</b> , 13, 198-200	14.9	4
97	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on Irenal biopsy. <i>Kidney International</i> , <b>2017</b> , 92, 1223-1231	9.9	40
96	Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids. <i>CKJ: Clinical Kidney Journal</i> , <b>2017</b> , 10, 233-239	4.5	24
95	The natural history of immunoglobulin M nephropathy in adults. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, 823-829	4.3	10
94	Familial vasculitides: granulomatosis with polyangitis and microscopic polyangitis in two brothers with differing anti-neutrophil cytoplasm antibody specificity. <i>CKJ: Clinical Kidney Journal</i> , <b>2016</b> , 9, 429-3	31 <sup>4·5</sup>	2
93	Human Chorionic Stem Cells: Podocyte Differentiation and Potential for the Treatment of Alport Syndrome. <i>Stem Cells and Development</i> , <b>2016</b> , 25, 395-404	4.4	13
92	ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. <i>PLoS ONE</i> , <b>2016</b> , 11, e0165402	3.7	15
91	CCL18 synergises with high concentrations of glucose in stimulating fibronectin production in human renal tubuloepithelial cells. <i>BMC Nephrology</i> , <b>2016</b> , 17, 139	2.7	4
90	Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. <i>Rheumatology</i> , <b>2016</b> , 55, 1437-42	3.9	19
89	A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 577-8	4 <sup>13.6</sup>	55
88	The role of monocytes in ANCA-associated vasculitides. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 1046-1053	13.6	21
87	Clinical trials. Rituximab for maintenance of remission in AAV. <i>Nature Reviews Nephrology</i> , <b>2015</b> , 11, 13	<b>1-2</b> 4.9	4
86	Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. <i>Kidney International</i> , <b>2015</b> , 88, 52-60	9.9	28
85	Clinical and Imaging Features of Lacrimal Gland Involvement in Granulomatosis with Polyangiitis.  Ophthalmology, 2015, 122, 2125-9	7.3	16

### (2014-2015)

84	Tissue Interleukin-17 and Interleukin-23 as Biomarkers for Orbital Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , <b>2015</b> , 122, 2140-2	7.3	7
83	Outcome and treatment of elderly patients with ANCA-associated vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2015</b> , 10, 1128-35	6.9	50
82	S100A8/A9 (calprotectin) is critical for development of glomerulonephritis and promotes inflammatory leukocyte-renal cell interactions. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 1264-74	5.8	23
81	Macrophage epoxygenase determines a profibrotic transcriptome signature. <i>Journal of Immunology</i> , <b>2015</b> , 194, 4705-4716	5.3	20
80	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. <i>Rheumatology</i> , <b>2015</b> , 54, 1025-32	3.9	8
79	Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. <i>Rheumatology</i> , <b>2015</b> , 54, 899-907	3.9	21
78	Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis. <i>Kidney International</i> , <b>2015</b> , 87, 807-11	9.9	18
77	Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 1185-92	4.3	69
76	Selective Targeting of a Disease-Related Conformational Isoform of Macrophage Migration Inhibitory Factor Ameliorates Inflammatory Conditions. <i>Journal of Immunology</i> , <b>2015</b> , 195, 2343-52	5.3	29
75	SURVEY OF STAFF OPINIONS ABOUT EXTENDED HAEMODIALYSIS TREATMENT TIME AND SERVICE IMPLICATIONS. <i>Journal of Renal Care</i> , <b>2015</b> , 41, 162-7	1.6	
74	Local IL-17 Production Exerts a Protective Role in Murine Experimental Glomerulonephritis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136238	2.7	7
	ONL, <b>2013</b> , 10, <del>20</del> 130238	3.7	/
73	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2015, 30, iii317-iii317	4.3	,
73 72	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. <i>Nephrology</i>		9
	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, iii317-iii317  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by	4.3	
72	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, iii317-iii317  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. <i>Journal of Autoimmunity</i> , <b>2015</b> , 59, 8-18  Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on	4·3 15.5	9
7 <sup>2</sup>	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2015, 30, iii317-iii317  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. Journal of Autoimmunity, 2015, 59, 8-18  Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease. Ophthalmology, 2015, 122, 1262-8	4·3 15.5	9
72 71 70	FP721RISING GLOBAL INCIDENCE OF HEMORRHAGIC STROKE IN HEMODIALYSIS. Nephrology Dialysis Transplantation, 2015, 30, iii317-iii317  Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. Journal of Autoimmunity, 2015, 59, 8-18  Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis: Impact on Localized and Nonlocalized Disease. Ophthalmology, 2015, 122, 1262-8  Goodpasture Syndrome and Other Antiglomerular Basement Membrane Diseases 2014, 193-197  Clinical and imaging features predictive of orbital granulomatosis with polyangiitis and the risk of	4·3 15·5 7·3	9 44

66	The heterogeneous mononuclear phagocyte system of the kidney. Kidney International, 2014, 85, 1011-	<b>4</b> 9.9	4
65	Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , <b>2014</b> , 53, 1693-703	3.9	46
64	Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2014</b> , 25, 2291-302	12.7	41
63	Exaggerated renal fibrosis in P2X4 receptor-deficient mice following unilateral ureteric obstruction. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 1350-61	4.3	21
62	L46. Novel forms of clinical vasculitis: anti-GBM vasculitis (Goodpasture's disease). <i>Presse Medicale</i> , <b>2013</b> , 42, 625-8	2.2	3
61	B-cell-targeted therapy in adult glomerulonephritis. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 169	1 <sub>5</sub> 7.06	10
60	Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. <i>Kidney International</i> , <b>2013</b> , 83, 1150-8	9.9	50
59	Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , <b>2012</b> , 51, 634-43	3.9	85
58	Genetic susceptibility to experimental autoimmune glomerulonephritis in the Wistar Kyoto rat. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 1843-51	5.8	12
57	Plasmapheresis in immunologic renal disease. <i>Blood Purification</i> , <b>2012</b> , 33, 190-8	3.1	32
56	Genetically distinct subsets within ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 214-23	59.2	627
55	Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2012</b> , 27, 1343-50	4.3	21
54	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 488-94	2.4	501
53	Crescentic glomerulonephritis: new aspects of pathogenesis. <i>Seminars in Nephrology</i> , <b>2011</b> , 31, 361-8	4.8	44
52	Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2011</b> , 26, 3280-6	4.3	47
51	Ocular manifestations of Wegener granulomatosis. Expert Review of Ophthalmology, 2011, 6, 541-555	1.5	5
50	Management of ANCA-associated vasculitis: Current trends and future prospects. <i>Therapeutics and Clinical Risk Management</i> , <b>2010</b> , 6, 253-64	2.9	30
49	Serum IL-17 and IL-23 levels and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 2209-17	4.3	160

### (2003-2010)

48	Histopathologic classification of ANCA-associated glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1628-36	12.7	492
47	Kallikreins: unravelling the genetics of autoimmune glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 2987-9	4.3	
46	Renal & ocular targets for therapy in Wegener's granulomatosis. <i>Inflammation and Allergy: Drug Targets</i> , <b>2009</b> , 8, 70-9		5
45	Goodpasture Syndrome and Other Anti Clomerular Basement Membrane Disease 2009, 186-190		
44	Regulation of inflammation and scarring in glomerulonephritis. <i>International Journal of Experimental Pathology</i> , <b>2008</b> , 85, A14-A14	2.8	
43	Ocular manifestations of Wegener granulomatosis. Expert Review of Ophthalmology, 2007, 2, 91-103	1.5	2
42	Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2007</b> , 18, 2180-8	12.7	772
41	Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 1243-52	12.7	49
40	Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 160-9	12.7	92
39	The continuing challenge of anti-neutrophil cytoplasm antibody-associated systemic vasculitis and glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2006</b> , 17, 1221-3	12.7	3
38	Drug insight: rituximab in renal disease and transplantation. <i>Nature Clinical Practice Nephrology</i> , <b>2006</b> , 2, 221-30		97
37	Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. <i>Blood</i> , <b>2005</b> , 106, 2050-8	2.2	210
36	Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: an update on approaches to management. <i>Nephrology</i> , <b>2005</b> , 10, 368-76	2.2	21
35	Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. <i>Nephrology Dialysis Transplantation</i> , <b>2004</b> , 19, 2761-8	4.3	<del>7</del> 2
34	Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2004</b> , 15, 717-21	12.7	292
33	Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. <i>Kidney International</i> , <b>2004</b> , 66, 1535-40	9.9	215
32	Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. <i>American Journal of Kidney Diseases</i> , <b>2003</b> , 41, 776-84	7.4	351
31	Anti-glomerular basement membrane disease. <i>Kidney International</i> , <b>2003</b> , 64, 1535-50	9.9	142

30	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. <i>Kidney International</i> , <b>2003</b> , 64, 1685-94	9.9	76
29	Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies. <i>American Journal of Clinical Pathology</i> , <b>2003</b> , 120, 312-318	1.9	140
28	A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 36-44	59.2	1024
27	Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. <i>American Journal of Clinical Pathology</i> , <b>2003</b> , 120, 312-8	1.9	45
26	Segregation of experimental autoimmune glomerulonephritis as a complex genetic trait and exclusion of Col4a3 as a candidate gene. <i>Nephron Experimental Nephrology</i> , <b>2002</b> , 10, 402-7		20
25	Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. <i>American Journal of Kidney Diseases</i> , <b>2002</b> , 39, 1162-7	7.4	124
24	Immunology of anti-glomerular basement membrane disease. <i>Current Opinion in Nephrology and Hypertension</i> , <b>2002</b> , 11, 279-86	3.5	25
23	Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1265-72	5.8	34
22	Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2002</b> , 13, 359-369	12.7	63
21	Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 1033-42	8	368
20	Cellular aspects of vasculitisT cell-mediated aspects. <i>Seminars in Immunopathology</i> , <b>2001</b> , 23, 287-98		3
19	Multisorbent plasma perfusion in fulminant hepatic failure: effects of duration and frequency of treatment in rats with grade III hepatic coma. <i>Artificial Organs</i> , <b>2001</b> , 25, 109-18	2.6	7
18	Bone marrow contributes to renal parenchymal turnover and regeneration. <i>Journal of Pathology</i> , <b>2001</b> , 195, 229-35	9.4	550
17	Plasmapheresis in Antineutrophil Cytoplasmic Antibodies-Associated Systemic Vasculitis. <i>Therapeutic Apheresis and Dialysis</i> , <b>2001</b> , 5, 176-181		11
16	Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 518-24	4.3	76
15	Expression and characterization of recombinant rat alpha 3(IV)NC1 and its use in induction of experimental autoimmune glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , <b>2001</b> , 16, 253-61	4.3	37
14	Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. <i>Journal of Immunology</i> , <b>2001</b> , 166, 6820-8	5.3	73
13	Goodpasture's disease. <i>Lancet, The</i> , <b>2001</b> , 358, 917-20	40	126

#### LIST OF PUBLICATIONS

12	Interleukin-11 attenuates nephrotoxic nephritis in Wistar Kyoto rats. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 2310-2320	12.7	24
11	Oral administration of glomerular basement membrane prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 61-70	12.7	35
10	In Goodpasture's disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2001</b> , 12, 1908-1915	12.7	60
9	CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, 643-51	15.9	141
8	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). <i>American Journal of Clinical Pathology</i> , <b>1999</b> , 111, 507-13	1.9	466
7	Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. <i>Kidney International</i> , <b>1999</b> , 55, 1319-26	9.9	42
6	Plasma immunoreactive leptin concentration in end-stage renal disease. Clinical Science, 1997, 93, 119-	<b>26</b> .5	57
5	T cell responses in ANCA-positive vasculitis. <i>Nephrology</i> , <b>1997</b> , 3, s778-s779	2.2	
4	Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. <i>Kidney International</i> , <b>1997</b> , 51, 222-9	9.9	88
3	Succinylated gelatin as partial fluid replacement in chronic therapeutic plasma exchange. <i>Journal of Clinical Apheresis</i> , <b>1992</b> , 7, 124-5	3.2	
2	Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. <i>Kidney International</i> , <b>1991</b> , 40, 757-63	9.9	247
1	Repeated membrane plasma separation with on-line sorbent treatment of plasma in the conscious rat. <i>Artificial Organs</i> , <b>1986</b> , 10, 135-44	2.6	12